Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section

Ostermann, Marlies; Schneider, Antoine; Rimmelé, Thomas; Bobek, Ilona; Dam, Marjel van; Darmon, Michaël; Forni, Lui G.; Joannès-Boyau, Olivier; Joannidis, Michael; Legrand, Matthieu; Prowle, John R.; Zarbock, Alexander; Hoste, Eric

doi:10.1186/s40635-019-0280-z

Cited by 7 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, alternative AKI biomarkers have been intensively studied for more than 20 years. In general, three groups of biomarkers must be distinguished: markers of stress, structural damage, or excretory (dys)function [ 27 ]. Currently, the third group is exclusively represented by cystatin C [ 28 ] and proenkephalin A [ 29 ].…”

Section: Acute Kidney Injurymentioning

confidence: 99%

Metabolomics in Acute Kidney Injury: The Clinical Perspective

Patschan

Matyukhin

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Acute kidney injury (AKI) affects increasing numbers of hospitalized patients worldwide. The diagnosis of AKI is made too late in most individuals since it is still based on dynamic changes in serum creatinine. In recent years, new AKI biomarkers have been identified; however, none of these can reliably replace serum creatinine yet. Metabolomic profiling (metabolomics) allows the concomitant detection and quantification of large numbers of metabolites from biological specimens. The current article aims to summarize clinical studies on metabolomics in AKI diagnosis and risk prediction. Methods: The following databases were searched for references: PubMed, Web of Science, Cochrane Library, and Scopus, and the period lasted from 1940 until 2022. The following terms were utilized: ‘AKI’ OR ‘Acute Kidney Injury’ OR ‘Acute Renal Failure’ AND ‘metabolomics’ OR ‘metabolic profiling’ OR ‘omics’ AND ‘risk’ OR ‘death’ OR ‘survival’ OR ‘dialysis’ OR ‘KRT’ OR ‘kidney replacement therapy’ OR ‘RRT’ OR ‘renal replacement therapy’ OR ‘recovery of kidney function’ OR ‘renal recovery’ OR ‘kidney recovery’ OR ‘outcome’. Studies on AKI risk prediction were only selected if metabolomic profiling allowed differentiation between subjects that fulfilled a risk category (death or KRT or recovery of kidney function) and those who did not. Experimental (animal-based) studies were not included. Results: In total, eight studies were identified. Six studies were related to the diagnosis of AKI; two studies were performed on metabolic analysis in AKI risk (death) prediction. Metabolomics studies in AKI already helped to identify new biomarkers for AKI diagnosis. The data on metabolomics for AKI risk prediction (death, KRT, recovery of kidney function), however, are very limited. Conclusions: Both the heterogenous etiology and the high degree of pathogenetic complexity of AKI most likely require integrated approaches such as metabolomics and/or additional types of ‘-omics’ studies to improve clinical outcomes in AKI.

show abstract

Section: Acute Kidney Injurymentioning

confidence: 99%

Metabolomics in Acute Kidney Injury: The Clinical Perspective

Patschan

Matyukhin

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Significant advances have been made in extracorporeal blood purification (EBP) due to new technologies, refined biomaterials, an improved understanding of the benefits and challenges of these techniques, and new indications [1][2][3][4][5][6][7][8][9]. However, large-scale randomized clinical trials are lacking for most technologies, and major variability exists in current practice worldwide [10,11]. Furthermore, there is considerable misunderstanding of EBP therapy, which is exacerbated by significant inconsistencies in terminology used for the different techniques, devices, and components.…”

Section: Introductionmentioning

confidence: 99%

Nomenclature of Extracorporeal Blood Purification Therapies for Acute Indications: The Nomenclature Standardization Conference

Ostermann,

Ankawi,

Cantaluppi

et al. 2023

Blood Purif

View full text Add to dashboard Cite

The development of new extracorporeal blood purification (EBP) techniques has led to increased application in clinical practice but also inconsistencies in nomenclature and misunderstanding. In November 2022, an international consensus conference was held to establish consensus on the terminology of EBP therapies. It was agreed to define EBP therapies as techniques that use an extracorporeal circuit to remove and/or modulate circulating substances to achieve physiological homeostasis, including support of the function of specific organs and/or detoxification. Specific acute EBP techniques include renal replacement therapy, isolated ultrafiltration, hemoadsorption, and plasma therapies, all of which can be applied in isolation and combination. This paper summarizes the proposed nomenclature of EBP therapies and serves as a framework for clinical practice and future research.

show abstract